DK0565377T3 - Therapeutic agents for the treatment of Parkinson's disease - Google Patents

Therapeutic agents for the treatment of Parkinson's disease

Info

Publication number
DK0565377T3
DK0565377T3 DK93302780.7T DK93302780T DK0565377T3 DK 0565377 T3 DK0565377 T3 DK 0565377T3 DK 93302780 T DK93302780 T DK 93302780T DK 0565377 T3 DK0565377 T3 DK 0565377T3
Authority
DK
Denmark
Prior art keywords
group
parkinson
disease
treatment
therapeutic agents
Prior art date
Application number
DK93302780.7T
Other languages
Danish (da)
Inventor
Akio Ishii
Fumio Suzuki
Shunji Ichikawa
Junichi Shimada
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK0565377T3 publication Critical patent/DK0565377T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Abstract

Disclosed are therapeutic agents for use in the treatment of Parkinson's disease, such agents being xanthine derivatives of the Formula (I) and their pharmaceutical acceptable salts: <CHEM> where R<1>, R<2> and R<3> are each H, C1-C6 alkyl or allyl; and R<4> is cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R<5> group where n is an cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R<5> group where n is an integer of from 0-4 and R<5> is an aryl group of 6 to 10 carbon atoms or a heterocyclic group, such aryl or heterocyclic group optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino; or a <CHEM> group, where Y<1> and Y<2> are each H or CH3 and Z is a substituted or unsubstituted aryl or heterocyclic group as defined under R<5>.
DK93302780.7T 1992-04-08 1993-04-08 Therapeutic agents for the treatment of Parkinson's disease DK0565377T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (1)

Publication Number Publication Date
DK0565377T3 true DK0565377T3 (en) 1998-03-16

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93302780.7T DK0565377T3 (en) 1992-04-08 1993-04-08 Therapeutic agents for the treatment of Parkinson's disease

Country Status (11)

Country Link
EP (1) EP0565377B1 (en)
JP (1) JP2613352B2 (en)
AT (1) ATE161723T1 (en)
BR (1) BR1100636A (en)
CA (1) CA2093403C (en)
DE (1) DE69316067T2 (en)
DK (1) DK0565377T3 (en)
ES (1) ES2112386T3 (en)
GR (1) GR3026233T3 (en)
HK (1) HK1001835A1 (en)
NO (1) NO303265B1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016604A1 (en) * 1992-02-19 1993-09-02 Yukio Ishida Highly water absorbing rice, method of manufacturing same and utilization thereof
ATE216584T1 (en) * 1992-07-08 2002-05-15 Kyowa Hakko Kogyo Kk XANTHINE DERIVATIVES AS ANTIDEPRESSANTS
JP2613355B2 (en) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 Parkinson's disease treatment
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
CA2160928C (en) * 1993-07-28 2005-07-05 Garry Fenton Compounds as pde iv and tnf inhibitors
DE69526822T2 (en) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo Kk Xanthine derivatives
AU3784597A (en) * 1996-08-07 1998-02-25 Kyowa Hakko Kogyo Co. Ltd. Fat emulsion containing xanthine derivative
EP1666041A3 (en) 1997-09-05 2008-04-02 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating neurodegenerative disorders
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
AR044069A1 (en) 2003-04-25 2005-08-24 Nova Cardia Inc A METHOD OF IMPROVED DIURESIS IN INDIVIDUALS WITH DETERIORATED RENAL FUNCTION
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2005072739A1 (en) 2004-01-28 2005-08-11 Kyowa Hakko Kogyo Co., Ltd. Drug for treating migraine
KR20080004550A (en) * 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
JP2008536919A (en) * 2005-04-22 2008-09-11 ノヴァカーディア，インク． Production of emulsions of pharmaceutical compositions
JP2010513353A (en) * 2006-12-22 2010-04-30 シュバルツ ファルマ アクチェンゲゼルシャフト 8-Ethynylxanthine derivatives as selective A2A receptor antagonists
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111333648B (en) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-substituted aromatic ring vinyl xanthine derivative and application thereof
CN110041331B (en) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 Styrylxanthine derivative and use thereof
CN112409360B (en) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 Heteroaryl vinyl xanthine derivatives and uses thereof
WO2021093701A1 (en) * 2019-11-11 2021-05-20 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111018856B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-substituted styrylxanthine derivatives and uses thereof
CN111072663B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-substituted styrylxanthine derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2059577B1 (en) * 1969-07-30 1973-08-10 Parke Davis & Co
DE3843117A1 (en) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg NEW XANTHINE DERIVATIVES WITH ADENOSINE ANTAGONISTIC EFFECT
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (en) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders
FR2665636B1 (en) * 1990-08-10 1994-10-07 Adir USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE.
CA2094270C (en) * 1990-10-18 1997-01-21 Fumio Suzuki Xanthine derivatives

Also Published As

Publication number Publication date
ATE161723T1 (en) 1998-01-15
ES2112386T3 (en) 1998-04-01
JPH0616559A (en) 1994-01-25
EP0565377A1 (en) 1993-10-13
HK1001835A1 (en) 1998-07-10
NO931317L (en) 1993-10-11
JP2613352B2 (en) 1997-05-28
CA2093403C (en) 1999-08-10
EP0565377B1 (en) 1998-01-07
DE69316067T2 (en) 1998-07-02
CA2093403A1 (en) 1993-10-09
NO303265B1 (en) 1998-06-22
DE69316067D1 (en) 1998-02-12
NO931317D0 (en) 1993-04-06
BR1100636A (en) 2000-04-18
GR3026233T3 (en) 1998-05-29

Similar Documents

Publication Publication Date Title
DK0565377T3 (en) Therapeutic agents for the treatment of Parkinson&#39;s disease
DK0590919T3 (en) Therapeutic agents for Parkinson&#39;s disease
DE69418704D1 (en) ANTHRANILE ACID DERIVATIVES
DE69130120D1 (en) Cyclic amide derivatives
DE69331843T2 (en) Xanthine derivatives as antidepressants
ATE34976T1 (en) ARYLCYCLOBUTYLALKYLAMINES AND THEIR USE AS ANTIDEPRESSIVE DRUGS.
FI884088A (en) FOERFARANDE FOER FRAMSTAELLNING AV 17-SUBSTITUERADE ANDROSTA-1,4-DIEN-3-ONDERIVAT.
DE69230498T2 (en) 2-pyrazinylethylamine derivatives and their use as medicines.
DE69110217D1 (en) Derivatives of caffeine acid and pharmaceutical compositions containing them.
DE69626624T2 (en) DRUGS AGAINST TRHOMBOCYTOPENIA
DK0461012T3 (en) Derivatives of ((1-arylpyrrolidin-2-yl) methyl) piperazine, its preparation and their therapeutic use
DE69301639D1 (en) Tetrahydronaphthalene derivatives, their preparation and their therapeutic use